Familial pancreatic cancer - Status quo

International Journal of Colorectal Disease

Volumn 29, Issue 2, 2014, Pages 139-145

  Fendrich, Volker ^a   Langer, Peter ^a   Bartsch, Detlef K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Familial pancreatic cancer; Genetics; IPMN; Mutation; Pancreatectomy; PanIN; Screening

Indexed keywords

EARLY DETECTION OF CANCER; FAMILY; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 84895073126     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-013-1760-3     Document Type: Review

References (95)

1. Ehrenthal D, Haeger L, Griffin T, Compton C (1987) Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 59:1661-1664
2. MacDermott RP, Kramer P (1973) Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65:137-139
3. Reimer RR, Fraumeni JF Jr, Ozols RF, Bender R (1977) Pancreatic cancer in father and son. Lancet 23:1911
4. Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr, Smyrk T, Fitzsimmons ML, McClellan J (1989) Familial pancreatic cancer (part 1): genetic pathology review. Nebr Med J 74:109-112
5. Hruban RH, Petersen GM, Ha PK, Kern SE (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1-23
6. Applebaum SE, Kant JA, Whitcomb DC, Ellis IH (2000) Genetic testing. Counselling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575-588
7. Bartsch DK, et al. (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510-516
8. Del Chiaro M, et al. (2010) Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian registry. Dig Liver Dis 42:597-605
9. Hruban RH, Canto MI, Goggins M, Schulik R, Klein AP (2010) Update on familial pancreatic cancer. Adv Surg 44:293-311
10. Del Chiaro M, et al. (2007) Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 7:459-469
11. Bartsch DK, et al. (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 20:110902-110906
12. Hemminki K, Li X (2003) Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 10:525-530
13. Permuth-Wey J, Egan KM (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and metaanalysis. Fam Cancer 8:109-117
14. Bartsch DK (2003) Familial pancreatic cancer. Br J Surg 90:386-387
15. Jenne DE, et al. (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18:38-43
16. Giardiello FM, et al. (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 316:1511-1514
17. Goldstein AM, et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 12:333970-333974
18. Whelan AJ, Bartsch DK, Goodfellow PJ (1995) Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 12:333975-333977
19. Lynch HT, et al. (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 1:9484-9496
20. Bartsch DK, et al. (2010) Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. Clin Genet 77:333-41
21. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 15:87809-87811
22. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316
23. van Asperen CJ, et al. (2005) Cancer risk in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711-719
24. Thompson D, Easton DF (2002) Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365
25. Moran A, et al. (2011) Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 11:235-42
26. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF (1985) Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 52:271-273
27. Aarnio M, et al. (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218
28. Kastrinos F, et al. (2009) Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790-1795
29. Maire F, et al. (2002) Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 51:446-449
30. Giardello FM, et al. (1993) Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34:1394-1396
31. Whitcomb D, et al. (1996) Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 14:141-145
32. Witt H, et al. (2000) Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 25:213-216
33. Lowenfels AB, Maisonneuve P, Whitcomb DC (2000) Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am 84:565-573
34. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP (2001) Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 11:286169-286170
35. Maisonneuve P, Marshall BC, Lowenfels AB (2007) Risk of pancreatic cancer in patients with cystic fibrosis. Gut 56:1327-1328
36. Brand RE, et al. (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460-1469
37. Lynch HT, Brand RE, Deters CA, Shaw TG, Lynch JF (2001) Hereditary pancreatic cancer. Pancreatology 1:466-471
38. Hruban RH, et al. (1999) Familial pancreatic cancer. Ann Oncol 10:69-73
39. Schneider R, et al. (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10:323-330
40. Greenhalf W, et al. (2006) Anticipation in familial pancreatic cancer. Gut 55:252-258
41. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA (2003) Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 124:1292-1299
42. Wang L, et al. (2009) Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomark Prev 18:2829-2834
43. Klein AP, et al. (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634-2638
44. Tersmette AC, et al. (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738-744
45. Brune KA, et al. (2010) Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 102:119-126
46. Aichler M, et al. (2013) Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 226:723-34
47. Brune K, et al. (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Path 30:1067-1076
48. Shi C, et al. (2009) Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 15:7737-7743
49. Langer P, Gress TM, Bartsch DK (2010) Pancreatic cancer screening in individuals at risk - too early for a general implementation on a health care basis. Gut 59:1006-1007
50. Ingkakul T, Sadakari Y, Jenaga J, Satho N, Takahata S, Tanaka M (2010) Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 251:70-75
51. Uehara H, et al. (2008) Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57:1561-1565
52. Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM (2002) Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 23:133-137
53. Eberle MA, et al. (2002) A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 70:1044-1048
54. Pogue-Geile KL, et al. (2006) Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3:e516
55. Slater E, et al. (2007) Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 4:e164
56. Klein AP, et al. (2009) Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomark Prev 18:1328-1330
57. Bartsch DK, et al. (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730-737
58. Slater E, et al. (2010) Prevalence of BRCA2 and CDKN2a mutations in German Familial pancreatic cancer families. Fam Cancer 9:335-343
59. Hahn SA, et al. (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221
60. Murphy KM, et al. (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789-3793
61. Couch FJ, et al. (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomark Prev 16:342-346
62. Skoulidis F, et al. (2010) Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18:499-509
63. Rowley M, et al. (2011) Inactivation of BRCA2 promotes TP53-asociated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 140:1303-1313
64. Feldmann G, et al. (2011) Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther 11:959-968
65. Bryant HE, et al. (2005) Specific killing of BRCA2-deficient tumors with inhibitors of poly (ADP-ribose) polymerase. Nature 434:913-917
66. James E, Waldron-Lynch MG, Saif MW (2009) Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 20:634-638
67. Jones S, et al. (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217-220
68. Slater EP, et al. (2010) PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78:490-494
69. Harinck F, et al. (2012) Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet 20:577-9
70. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE (2003) Fanconi anemia gene mutations in young onset pancreatic cancer. Cancer Res 63:2585-2588
71. Couch FJ, et al. (2005) Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65:383-386
72. Roberts NJ, et al. (2011) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2:41-46
73. Axilbund JE, Brune KA, Canto MI, Brehon BC, Wroblewski LD, Griffin CA (2005) Patient perspective on the value of genetic counselling for familial pancreas cancer. Hered Cancer Clin Pract 3:115-122
74. Wang W, Chen S, Brune KA, et al. (2007) PancPRO: risk assessment in individuals with a family history of pancreatic cancer. J Clin Oncol 25:1417-1422
75. Leonardi M, et al. (2012) "PancPro" as a tool for selecting families eligible for pancreatic cancer screening: an Italian study of incident cases. Dig Liver Dis 44:585-8
76. American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406
77. Canto MI, et al. (2012) On behalf of the International CAPS Consortium International Consensus Recommendations on the management of patients with increased risk for familial pancreatic cancer (Cancer of the Pancreas Screening Consortium (CAPS) 2011 Summit). To be presented at the Digestive Disease Week (DDW), San Diego, California, USA, May 19-22
78. Bussom S, Saif MW (2010) Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". JOP 11:128-130
79. Brentnall TA, et al. (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131:247-255
80. Kimmey MB, et al. (2002) Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56:S82-S86
81. Canto MI, et al. (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2:606-621
82. Canto MI, et al. (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766-781
83. Poley JW, et al. (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175-2181
84. Langer P, et al. (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58:1410-1418
85. Verna EC, et al. (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028-5037
86. Canto MI, et al. (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142:796-804
87. Rulyak SJ, et al. (2001) Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 1:477-485
88. Raut CP, et al. (2003) Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J GastrointestSurg 7:118-126
89. Ludwig E, et al. (2011) Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 106:946-954
90. Al-Sukhni W, et al. (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16:771-783
91. Vasen HF, et al. (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140:850-856
92. Sutherland DE, Matas AJ, Najarian JS (1977) Pancreas and islet transplantation. World J Surg 2:185
93. Harinck F, et al. (2011) Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 13:1015-1024
94. Hart SL, et al. (2012) Moderators of cancer related distress and worry after a pancreatic cancer genetic counselling and screening intervention. Psychooncology 21:1324-30. doi: 10.1002/pon.2026
95. Maheu C, et al. (2010) Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning. Fam Cancer 9:617-624